JPH07196525A - Preventing and therapeutic agent for gastritis, gastric and duodenal ulcer - Google Patents
Preventing and therapeutic agent for gastritis, gastric and duodenal ulcerInfo
- Publication number
- JPH07196525A JPH07196525A JP5353845A JP35384593A JPH07196525A JP H07196525 A JPH07196525 A JP H07196525A JP 5353845 A JP5353845 A JP 5353845A JP 35384593 A JP35384593 A JP 35384593A JP H07196525 A JPH07196525 A JP H07196525A
- Authority
- JP
- Japan
- Prior art keywords
- gastric
- gastritis
- duodenal ulcer
- therapeutic agent
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、胃炎、胃・十二指腸潰
瘍の原因物質の一つであるヘリコバクター・ピロリ（He
licobacter pylori）の増殖阻害作用を有する物質を有
効成分とする、胃炎、胃・十二指腸潰瘍の予防及び治療
剤に関し、更に詳しくは、トウガラシ、青皮、リュウタ
ン、ゴシュユ、ニガキ、セキショウコン、サンナから選
ばれる一種または複数の生薬を含有する胃炎、胃・十二
指腸潰瘍の予防及び治療剤に関する。TECHNICAL FIELD The present invention relates to Helicobacter pylori ( He) , which is one of the causative agents of gastritis and gastric / duodenal ulcer.
licobacter pylori ), which is a preventive and / or therapeutic agent for gastritis and gastric / duodenal ulcer, which contains a substance having an inhibitory effect on the growth of licobacter pylori. The present invention relates to a prophylactic and therapeutic agent for gastritis and gastric / duodenal ulcer containing one or more crude drugs.
【０００２】[0002]
【従来の技術】１９８３年に胃炎または消化性潰瘍患者
の胃粘膜生検組織からカンピロバクター・ピロリ（Camp
ylobacter pylori）が高率に見い出されることが報告
（WarrenJR. Marshall BJ: Lancet, 1273-1275, 1983）
されて以来、胃炎あるいは胃・十二指腸潰瘍の発症にカ
ンピロバクター・ピロリが関与していることが次第に明
らかになり、多くの研究報告がなされてきている。その
後、カンピロバクター・ピロリはヘリコバクター・ピロ
リと改名され、胃炎あるいは胃・十二指腸潰瘍疾患との
関連性が深いことが、臨床的にも明らかになってきた。BACKGROUND OF THE INVENTION 1983 to gastritis or peptic ulcer patients Campylobacter pylori from gastric mucosal biopsy specimens of (Camp
ylobacter pylori ) was found at a high rate (Warren JR. Marshall BJ: Lancet, 1273-1275, 1983)
Since then, it has become increasingly clear that Campylobacter pylori is involved in the development of gastritis or gastric / duodenal ulcer, and many research reports have been made. After that, Campylobacter pylori was renamed as Helicobacter pylori, and it has become clinically clear that it is closely related to gastritis or gastric / duodenal ulcer disease.
【０００３】ヘリコバクター・ピロリは胃粘膜に感染す
るグラム陰性のらせん状桿菌であり、強いウレアーゼ活
性を有し、宿主由来の胃内の尿素をアンモニアに分解し
て胃酸を中和し、当該菌の胃の中での生育を可能とす
る。また、ヘリコバクター・ピロリに分解されたアンモ
ニアが胃粘膜に対して障害性を持つことが近年報告さ
れ、胃炎あるいは胃・十二指腸潰瘍の原因の一つとして
注目されている。Helicobacter pylori is a gram-negative spiral bacterium that infects gastric mucosa, has a strong urease activity, decomposes urea in the stomach derived from the host into ammonia to neutralize gastric acid, and Allows growth in the stomach. In addition, it has been recently reported that ammonia decomposed into Helicobacter pylori has a gastrointestinal mucosal property, and has been attracting attention as one of the causes of gastritis or gastric / duodenal ulcer.
【０００４】以上のようなことから、胃炎あるいは胃・
十二指腸潰瘍の予防及び治療に抗ヘリコバクター・ピロ
リ活性を有する抗生物質等を利用しようとする試みが行
われてきた。これまでβラクタム剤（ペニシリン、アン
ピシリン等）、マクロライド剤（エリスロマイシン、ク
ラリスロマイシン等）、アミノグリコシド剤（ストレプ
トマイシン）、テトラサイクリン剤等の抗生物質及びビ
スマス製剤がヘリコバクター・ピロリに対して強い抗菌
作用を示すことが報告され、これらの投与が行われてき
た。また近年、Ｈ2−受容体拮抗剤、プロトンポンプ・
インヒビター等の抗潰瘍剤において、ヘリコバクター・
ピロリに対する抗菌活性を併せ持つ成分の開発が行わ
れ、製品化されつつある。しかしながら、これら従来の
抗生物質等の投与では、長期投与時の安全性あるいは再
発等の問題も多く、有効かつ安全な薬剤の開発が望まれ
ていた。これら従来の薬剤のうち、臨床的に応用されつ
つあるものもあるが、評価が一定せず、これまで有効か
つ安全で長期投与が可能な薬剤はなかった。From the above, gastritis or stomach
Attempts have been made to utilize antibiotics and the like having anti-Helicobacter pylori activity for the prevention and treatment of duodenal ulcer. Until now, antibiotics such as β-lactam agents (penicillin, ampicillin, etc.), macrolide agents (erythromycin, clarithromycin, etc.), aminoglycoside agents (streptomycin), tetracycline agents and bismuth agents have strong antibacterial action against Helicobacter pylori. It has been reported that these doses have been administered. In recent years, H 2 -receptor antagonists, proton pumps,
In anti-ulcer agents such as inhibitors, Helicobacter
Ingredients that also have antibacterial activity against Helicobacter pylori have been developed and are being commercialized. However, administration of these conventional antibiotics has many problems such as safety or recurrence during long-term administration, and development of effective and safe drugs has been desired. Although some of these conventional drugs are being clinically applied, the evaluation has not been constant, and thus far, there has been no drug effective and safe and capable of long-term administration.
【０００５】[0005]
【発明が解決しようとする課題】本発明の目的は、ヘリ
コバクター・ピロリの増殖を阻害することにより、胃炎
あるいは胃・十二指腸潰瘍の発症を防ぎ、治療するのに
有効かつ安全な胃炎、胃・十二指腸潰瘍の予防及び治療
剤を提供することにある。DISCLOSURE OF THE INVENTION The object of the present invention is to prevent the development of gastritis or gastric / duodenal ulcer by inhibiting the growth of Helicobacter pylori, and to treat gastritis, gastric / duodenal effective and safe. An object is to provide a preventive and therapeutic agent for ulcers.
【０００６】[0006]
【課題を解決するための手段】本発明者らは、前記課題
を解決するため、一般的に副作用が少なく、長期連用が
推奨されている生薬に着目し、ヘリコバクター・ピロリ
増殖阻害作用を有するより有用な胃炎あるいは胃・十二
指腸潰瘍予防及び治療剤を開発すべく鋭意研究した結
果、現在は他の用途に使用されているトウガラシ、青
皮、リュウタン、ゴシュユ、ニガキ、セキショウコン、
サンナにヘリコバクター・ピロリ増殖阻害作用があるこ
とを見い出し、本発明を完成するに至った。[Means for Solving the Problems] In order to solve the above problems, the present inventors have focused on crude drugs that generally have few side effects and are recommended for long-term continuous use, and have a Helicobacter pylori growth inhibitory effect. As a result of diligent research to develop a useful gastritis or gastroduodenal ulcer preventive and therapeutic agent, as a result, capsicum, blue peel, ryutan, goshuyu, bittern, broomweed, currently used for other purposes,
The inventors have found that Sanna has a Helicobacter pylori growth inhibitory action, and completed the present invention.
【０００７】即ち、本発明はヘリコバクター・ピロリの
増殖を阻害することにより、胃炎あるいは胃・十二指腸
潰瘍の発症を防ぎ、治療するのに有効かつ安全な胃炎、
胃・十二指腸潰瘍予防及び治療剤を提供するものであ
る。That is, the present invention inhibits the growth of Helicobacter pylori to prevent and treat the development of gastritis or the development of gastric / duodenal ulcer, and gastritis effective and safe,
The present invention provides a preventive and therapeutic agent for gastric and duodenal ulcer.
【０００８】本発明において、上記記載の生薬原料を粉
末にして、あるいは抽出エキスにして用いることができ
る。粉末の調製法については、生薬原料の形質及び成分
等の諸条件（生薬成分の熱安定性、油脂成分の多いも
の、繊維質の強いもの、芳香性成分の揮散の恐れのある
もの、含水度の高いもの、希望粒度等）を加味して選定
する。粉砕方法としては、生薬原料を直接あるいは凍結
した後、アトマイザー、ハンマーミル、スタンプミル、
ボールミル等を用いて粉砕する。粉砕工程を経た粉砕物
から希望粒度の粉末を得るため、ジャイロ型シフターあ
るいは振動篩等の篩過機により篩過を行う。抽出エキス
の調製法としては、例えば、上記原料の粗砕物を抽出溶
媒中で冷浸し、濾過して濾液を得る。残留物については
上記冷浸、濾過を２〜３回繰り返す。得られた濾液を合
わせ、抽出溶媒を留去した後、濃縮してエキスを得る。
抽出溶媒としては例えば、水、メタノール及びエタノー
ル等のアルコール類、酢酸エチル、アセトン並びにこれ
らの混合物等が挙げられるが、好ましくはエタノールで
ある。抽出溶媒の使用量は原料の粗砕物１重量部に対し
て２〜１０重量部、好ましくは２〜４重量部である。冷
浸温度及び時間は５〜４０℃で、好ましくは１５〜２５
℃で、１日〜３週間、好ましくは５日〜８日間である。
濃縮操作においては、常圧下でも減圧下でもよいが、濃
縮温度は４０℃以下で行うのが好ましい。In the present invention, the crude drug raw material described above can be used in the form of powder or extract. Regarding powder preparation methods, various conditions such as characteristics and ingredients of crude drug ingredients (heat stability of crude drug ingredients, those with a large amount of fats and oils, those with high fiber content, those with a risk of volatilization of aromatic components, water content) High quality, desired grain size, etc.). As a crushing method, an atomizer, a hammer mill, a stamp mill, after directly or freezing a crude drug raw material,
Grind using a ball mill or the like. In order to obtain a powder having a desired particle size from the pulverized product that has undergone the pulverization process, sieving is performed by a sieving machine such as a gyro type shifter or a vibration sieve. As a method for preparing the extract, for example, the coarsely crushed material of the above raw material is cold-soaked in an extraction solvent and filtered to obtain a filtrate. For the residue, the above cold soaking and filtration are repeated 2-3 times. The obtained filtrates are combined, the extraction solvent is distilled off, and then concentrated to obtain an extract.
Examples of the extraction solvent include water, alcohols such as methanol and ethanol, ethyl acetate, acetone, and a mixture thereof, with ethanol being preferable. The amount of the extraction solvent used is 2 to 10 parts by weight, preferably 2 to 4 parts by weight, based on 1 part by weight of the raw material crushed product. Cold immersion temperature and time are 5 to 40 ° C., preferably 15 to 25
The temperature is 1 ° C. to 3 weeks, preferably 5 days to 8 days.
The concentration operation may be performed under normal pressure or reduced pressure, but the concentration temperature is preferably 40 ° C. or lower.
【０００９】生薬抽出エキスは、そのまま、または希釈
あるいは濃縮し、もしくは凍結乾燥した後、粉末または
ペースト状に調製し、所望により適宜製剤化し、胃炎あ
るいは胃・十二指腸潰瘍予防剤及び治療剤として用いる
ことができる。製剤中の抽出エキスの含量は通常、０．
０１〜１０重量％である。The crude drug extract is used as it is, or after diluting or concentrating it, or after freeze-drying it, preparing it as a powder or paste, appropriately formulating it, and using it as a prophylactic and therapeutic agent for gastritis or gastric / duodenal ulcer. You can The content of the extract in the preparation is usually 0.
It is from 01 to 10% by weight.
【００１０】サンナについてその成分を分析した結果、
この生薬に含まれるp-メトキシケイヒ酸、ケイヒ酸エチ
ルエステル、およびp-メトキシケイヒ酸エチルエステル
が上記活性を有することが判明した。As a result of analyzing the components of Sanna,
It was found that p-methoxycinnamic acid, cinnamic acid ethyl ester, and p-methoxycinnamic acid ethyl ester contained in this crude drug have the above activity.
【００１１】サンナの活性成分の調製法としては、例え
ばp-メトキシケイヒ酸エチルエステルの場合、サンナの
エタノール抽出エキスを水に懸濁し、エーテルで抽出し
たエーテル層を濃縮乾固後、メタノールから再結晶する
ことによりエーテル移行部の主成分としてp-メトキシケ
イヒ酸エチルエステルを得る。ケイヒ酸エチルエステル
については、エーテル移行部よりｐ−メトキシケイヒ酸
エチルエステルを再結晶した後の母液よりシリカゲルカ
ラムクロマトグラフィにより単離する。ｐ−メトキシケ
イヒ酸については、サンナのエタノール抽出エキスを水
に懸濁し、ｎ−ブタノールで抽出したｎ−ブタノール層
よりシリカゲルカラムクロマトグラフィを用いて単離す
る。As a method for preparing the active ingredient of sanna, for example, in the case of p-methoxycinnamic acid ethyl ester, ethanol extract of sanna is suspended in water, the ether layer extracted with ether is concentrated to dryness, and then reconstituted from methanol. Crystallization gives p-methoxycinnamic acid ethyl ester as the main component of the ether transition part. The cinnamic acid ethyl ester is isolated by silica gel column chromatography from the mother liquor after recrystallizing p-methoxycinnamic acid ethyl ester from the ether transfer part. For p-methoxycinnamic acid, an ethanol extract of sanna is suspended in water, and isolated from the n-butanol layer extracted with n-butanol using silica gel column chromatography.
【００１２】製剤の剤型は特に限定されず、例えば錠
剤、カプセル剤、丸剤、顆粒剤及び液剤等であってよ
い。剤型に応じて、賦形剤等の添加剤を随意選択するこ
とができる。また、制酸剤、胃粘膜修復剤等の有効成分
を配合してもよい。これらの生薬の投与量は、例えば抽
出エキスの場合約０．１〜１０g／日（原生薬換算量）
であり、乾燥粉末の場合は約０．０１〜５g／日であ
る。ｐ−メトキシケイヒ酸、ケイヒ酸エチルエステル、
およびｐ−メトキシケイヒ酸エチルエステルの場合は約
１０ｍｇ〜３ｇ／日である。以下、実施例、試験例を挙
げて本発明を具体的に説明するが、本発明はこれらに限
定されるものではない。The dosage form of the preparation is not particularly limited and may be, for example, tablets, capsules, pills, granules and liquids. Additives such as excipients can be optionally selected depending on the dosage form. In addition, an active ingredient such as an antacid and a gastric mucosa repairing agent may be added. The dose of these crude drugs is, for example, about 0.1 to 10 g / day (the amount equivalent to the original drug) in the case of the extract.
And about 0.01 to 5 g / day for dry powder. p-methoxycinnamic acid, cinnamic acid ethyl ester,
And about 10 mg to 3 g / day for p-methoxycinnamic acid ethyl ester. Hereinafter, the present invention will be specifically described with reference to Examples and Test Examples, but the present invention is not limited thereto.
【００１３】[0013]
【実施例】実施例１ 生薬抽出エキスの作成方法 破砕した各種生薬それぞれ１００ｇに２〜３倍量のエタ
ノールを加え、ニガキについては、１０倍量のエタノー
ルを加え、室温にて１週間抽出した。同様の操作をさら
にもう一度繰り返した後、濾過により得られた抽出液を
濃縮乾固し、生薬抽出エキスを得た。原生薬から得られ
た抽出エキス量を表１に示した。尚、原生薬はすべて市
販のものを使用した。 Example 1 Method of preparing extract of crude drug Extract To 100 g of each crushed crude drug, 2 to 3 times amount of ethanol was added, and for nigaki, 10 times amount of ethanol was added and extracted for 1 week at room temperature. The same operation was repeated once more, and then the extract obtained by filtration was concentrated to dryness to obtain a crude drug extract. Table 1 shows the amount of the extract extracted from the original drug. In addition, all the crude drugs used were commercially available.
【表１】 ＊原生薬100g当たりのエキス含量（ｇ）[Table 1] * Extract content (g) per 100g of original drug
【００１４】試験例１ ヘリコバクタ−・ピロリの増
殖阻害効果の検討 培地：ブルセラブロス（ＢＢＬ社製）に馬血清を７％、
寒天を２％となるように添加し、20mlを三角フラスコに
とり、更に実施例１で調製した生薬抽出エキスを加え、
オートクレーブで滅菌した後、シャーレで固めた。 植菌：凍結保存したヘリコバクター・ピロリATCC 43504
株の懸濁液0.5mlをブルセラHK寒天培地（極東製薬工業
製）に塗布し、５日間培養した後、2mlの生理食塩水で
洗い、菌を集めた。そのうちの0.2mlを培地に塗布し
た。 培養：嫌気ジャー中にキャンピロパック（三菱瓦斯化学
製）を入れ、３７℃で５日間培養した。 判定：培養後、コントロールを+++とし、全く生えてい
ないものを−として阻害効果を５段階（+++，++，＋，
±，−）で評価した。 Test Example 1 Examination of growth inhibitory effect of Helicobacter pylori Medium: Brucella broth (manufactured by BBL) with 7% horse serum,
Agar was added to 2%, 20 ml was placed in an Erlenmeyer flask, and the crude drug extract prepared in Example 1 was further added.
After sterilizing with an autoclave, it was solidified with a petri dish. Inoculation: Cryopreserved Helicobacter pylori ATCC 43504
0.5 ml of the suspension of the strain was applied to Brucella HK agar medium (manufactured by Kyokuto Pharmaceutical Co., Ltd.), cultured for 5 days, and then washed with 2 ml of physiological saline to collect the bacteria. 0.2 ml of it was applied to the medium. Cultivation: Campylopak (manufactured by Mitsubishi Gas Chemical Co., Inc.) was placed in an anaerobic jar and cultured at 37 ° C. for 5 days. Judgment: After culturing, the control was set to +++, and the one that did not grow at all was set to −, and the inhibitory effect was divided into 5 levels (+++, ++, +,
It was evaluated by ±, −).
【００１５】実験はそれぞれ２回繰り返した。結果を表
２に示す。Each experiment was repeated twice. The results are shown in Table 2.
【表２】 [Table 2]
【００１６】結果：トウガラシ、青皮、リュウタン、ゴ
シュユ、ニガキ及びセキショウコンに増殖阻害作用が認
められた。サンナについては強い増殖阻害作用が認めら
れた。Results: A growth inhibitory effect was observed in capsicum, blue peel, ryutan, goshuyu, bitter melon, and broomweed. A strong growth inhibitory effect was observed for Sanna.
【００１７】試験例２ サンナ中の活性成分の探索 １）サンナ抽出エキスのヘリコバクター・ピロリの増殖
阻害効果の検討 サンナについては、実施例１で得たエタノール抽出エキ
スを水に懸濁後、エーテルで抽出した。エーテル層は濃
縮乾固した。水層は更にｎ−ブタノールで抽出し、ｎ−
ブタノール層と水層を得た。これらも同様に濃縮乾固
し、サンプルとし、試験例２に従ってヘリコバクタ−・
ピロリの増殖阻害活性を試験した。 Test Example 2 Search for Active Component in Sanna 1) Examination of Helicobacter pylori Growth Inhibitory Effect of Sanna Extract Extract Regarding Sanna, the ethanol extract extract obtained in Example 1 was suspended in water and then with ether. Extracted. The ether layer was concentrated to dryness. The aqueous layer was further extracted with n-butanol to give n-
A butanol layer and an aqueous layer were obtained. Similarly, these were also concentrated to dryness to prepare samples, and Helicobacter-
The growth inhibitory activity of H. pylori was tested.
【００１８】その結果を表３に示す。ヘリコバクタ−・
ピロリに対する増殖阻害活性は、エーテル移行部に強い
濃度依存性が認められた。The results are shown in Table 3. Helicobacter
The growth inhibitory activity against Helicobacter pylori was strongly dependent on the ether transition.
【表３】 サンナ抽出エキスのヘリコバクター・ピロリ増殖阻害活性 mg/ml培地 増 殖 サンナ H2O 2.5 ＋＋＋ n-BuOH 2.5 ＋＋ Ether 2.5 ＋ ２）サンナ活性成分のヘリコバクター・ピロリの増殖阻
害効果の検討 サンナにヘリコバクター・ピロリに対する強い増殖阻害
作用が認められたことから、サンナ中の既知成分である
p-メトキシケイヒ酸、ケイヒ酸エチルエステルおよびp-
メトキシケイヒ酸エチルエステルによる、ヘリコバクタ
−・ピロリの増殖阻害活性を試験例２によって調べた。[Table 3] Helicobacter pylori growth inhibitory activity of Sanna extract mg / ml medium Breeding sanna H 2 O 2.5 +++ n-BuOH 2.5 ++ Ether 2.5 + 2) Examination of the growth inhibitory effect of Helicobacter pylori, which is an active ingredient of sanna, Sanna was found to have a strong growth inhibitory effect against Helicobacter pylori. Is a known ingredient in Sanna
p-Methoxycinnamic acid, cinnamic acid ethyl ester and p-
The growth inhibitory activity of Helicobacter pylori by methoxycinnamic acid ethyl ester was examined by Test Example 2.
【００１９】結果を表４に示す。上記３成分に強い増殖
阻害作用のあることが認められた。The results are shown in Table 4. It was confirmed that the above three components have a strong growth inhibitory action.
【表４】 サンナ活性成分のヘリコバクタ−・ピロリの増殖阻害活性 サンナ活性成分 濃 度 増 殖 p-メトシキケイヒ酸 0.25mg/ml − ケイヒ酸エチルエステル 0.50mg/ml − p-メトシキケイヒ酸エチルエステル 0.25mg/ml − [Table 4] Growth inhibitory activity of Helicobacter pylori, an active ingredient of sanna Sanna Active ingredient Concentration Increase p-methoxycinnamate 0.25 mg / ml- Ethyl cinnamate 0.50 mg / ml- p-Methoxycinnamate ethyl 0.25 mg / ml-
【００２０】 [0020]
【００２１】ゴシュユ及びサンナは実施例１で調製した
生薬抽出エキスを用い、結晶セルロースと上記の割合で
混合、乾燥した後、打錠する。錠剤の場合はこれを粉砕
し、ステアリン酸マグネシウムを１％の割合となるよう
に混合し、打錠する。カプセル剤の場合は、打錠前の混
合粉をカプセル充填機にて第１号カプセルに充填する。
１回服用量は１錠あるいは１カプセルとする。For Goshuyu and Sanna, the crude drug extract prepared in Example 1 was used, mixed with crystalline cellulose in the above proportions, dried and compressed into tablets. In the case of tablets, this is crushed, magnesium stearate is mixed at a ratio of 1%, and compressed into tablets. In the case of capsules, the No. 1 capsule is filled with the mixed powder before tableting using a capsule filling machine.
The dose should be 1 tablet or 1 capsule.
【００２２】実施例３ 錠剤／カプセル剤 組成 ケイヒ酸エチルエステル １０ mg ステアリン酸マグネシウム ２．５mg 結晶セルロース 適 量 ２５０ mg／錠 Example 3 Tablet / capsule composition Ceramic acid ethyl ester 10 mg Magnesium stearate 2.5 mg Crystalline cellulose Appropriate amount 250 mg / tablet
【００２３】ケイヒ酸エチルエステル（東京化成工業
製）を結晶セルロースと上記の割合で混合、乾燥した
後、打錠する。錠剤の場合はこれを粉砕し、ステアリン
酸マグネシウムを１％の割合となるように混合し、打錠
する。カプセル剤の場合は、打錠前の混合粉をカプセル
充填機にて第２号カプセルに充填する。１回服用量は１
錠あるいは１カプセルとする。Ethyl cinnamic acid ester (manufactured by Tokyo Kasei Kogyo) is mixed with crystalline cellulose in the above proportions, dried and then tabletted. In the case of tablets, this is crushed, magnesium stearate is mixed at a ratio of 1%, and compressed into tablets. In the case of capsules, the No. 2 capsule is filled with the mixed powder before tableting using a capsule filling machine. The dose is 1
Take one tablet or one capsule.
【００２４】 [0024]
【００２５】実施例１で調製した生薬抽出エキスを用
い、他の成分を上記の割合で混合した後、適量の水を加
え練合、造粒を行う。造粒物は流動層乾燥機にて乾燥
し、整粒の後、着香剤として微量のｌ−メントールを添
加し、分包する。１回服用量は１包とする。 Using the crude drug extract prepared in Example 1, the other components are mixed in the above proportions, an appropriate amount of water is added, and the mixture is kneaded and granulated. The granulated product is dried in a fluidized bed drier, and after sizing, a small amount of 1-menthol is added as a flavoring agent and the product is packaged. The dose should be one packet.
【００２６】ｐ−メトキシケイヒ酸（東京化成工業製）
と他の成分を上記の割合で混合した後、適量の水を加え
練合、造粒を行う。造粒物は流動層乾燥機にて乾燥し、
整粒の後、着香剤として微量のトウヒ油を添加し、分包
する。１回服用量は１包とする。 P-Methoxycinnamic acid (manufactured by Tokyo Chemical Industry)
After mixing and other ingredients in the above proportions, an appropriate amount of water is added and kneaded to perform granulation. The granulated product is dried with a fluidized bed dryer,
After sizing, a small amount of spruce oil is added as a flavoring agent, and the mixture is packaged. The dose should be one packet.
【００２７】実施例１で調製した生薬抽出エキスを用
い、他の上記成分を加えて水に溶かして全量を６０mlと
して液剤を製した後、遮光したガラス瓶に充填し、製品
とする。Using the crude drug extract prepared in Example 1, the above ingredients were added and dissolved in water to make a total amount of 60 ml to prepare a liquid agent, which was then filled in a glass bottle protected from light to obtain a product.
【００２８】[0028]
【発明の効果】胃炎、胃・十二指腸潰瘍の原因物質の一
つであるヘリコバクター・ピロリの増殖阻害作用を有す
る生薬を使用することにより、胃炎、胃・十二指腸潰瘍
を予防及び治療することができる。EFFECTS OF THE INVENTION By using a crude drug having a growth inhibitory effect on Helicobacter pylori, which is one of the causative substances of gastritis and gastric / duodenal ulcer, gastritis and gastric / duodenal ulcer can be prevented and treated.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 31/215 9454−4Ｃ ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display location A61K 31/215 9454-4C
Claims (2)
pylori）の増殖阻害作用を有するトウガラシ、青皮、
リュウタン、ゴシュユ、ニガキ、セキショウコン及びサ
ンナから選ばれる一種または複数の生薬を含有すること
を特徴とする胃炎、胃・十二指腸潰瘍の予防及び治療
剤。[Claim 1] Helicobacter pylori (Helicobacter
pylori ), which has a growth-inhibitory effect,
A preventive and / or therapeutic agent for gastritis, gastric / duodenal ulcer, which comprises one or more crude drugs selected from Ryutan, Goshuyu, bittern, broom, and sanna.
ステル及びp-メトキシケイヒ酸エチルエステルから選ば
れる一種または複数の成分を含有することを特徴とする
胃炎、胃・十二指腸潰瘍の予防及び治療剤。2. A preventive and / or therapeutic agent for gastritis, gastric / duodenal ulcer, containing one or more components selected from p-methoxycinnamic acid, cinnamic acid ethyl ester and p-methoxycinnamic acid ethyl ester. .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP35384593A JP3547783B2 (en) | 1993-12-28 | 1993-12-28 | Prophylactic and therapeutic agent for gastritis and gastric / duodenal ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP35384593A JP3547783B2 (en) | 1993-12-28 | 1993-12-28 | Prophylactic and therapeutic agent for gastritis and gastric / duodenal ulcer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003401056A Division JP3991026B2 (en) | 2003-12-01 | 2003-12-01 | Preventive and therapeutic agent for gastritis and stomach / duodenal ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07196525A true JPH07196525A (en) | 1995-08-01 |
| JP3547783B2 JP3547783B2 (en) | 2004-07-28 |
Family
ID=18433611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP35384593A Expired - Fee Related JP3547783B2 (en) | 1993-12-28 | 1993-12-28 | Prophylactic and therapeutic agent for gastritis and gastric / duodenal ulcer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3547783B2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2135858A4 (en) * | 2007-03-02 | 2012-02-08 | Univ Zaragoza | Composition for teating infectious diseases |
| CN103892228A (en) * | 2014-04-21 | 2014-07-02 | 海南大学 | Preparation method of non-spicy sand ginger powder |
| CN103933174A (en) * | 2014-04-29 | 2014-07-23 | 福建农林大学 | Method for processing green tangerine peel decoction pieces with horse stale |
| CN105288441A (en) * | 2015-12-14 | 2016-02-03 | 华坚 | Sea-buckthorn traditional Chinese medicine composition with function of nourishing stomach and preparation method thereof |
| CN106814157A (en) * | 2017-01-17 | 2017-06-09 | 广州浩意万医药科技有限公司 | The preparation method of rascal reference extract |
-
1993
- 1993-12-28 JP JP35384593A patent/JP3547783B2/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2135858A4 (en) * | 2007-03-02 | 2012-02-08 | Univ Zaragoza | Composition for teating infectious diseases |
| CN103892228A (en) * | 2014-04-21 | 2014-07-02 | 海南大学 | Preparation method of non-spicy sand ginger powder |
| CN103933174A (en) * | 2014-04-29 | 2014-07-23 | 福建农林大学 | Method for processing green tangerine peel decoction pieces with horse stale |
| CN105288441A (en) * | 2015-12-14 | 2016-02-03 | 华坚 | Sea-buckthorn traditional Chinese medicine composition with function of nourishing stomach and preparation method thereof |
| CN106814157A (en) * | 2017-01-17 | 2017-06-09 | 广州浩意万医药科技有限公司 | The preparation method of rascal reference extract |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3547783B2 (en) | 2004-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT401346B (en) | METHOD FOR PRODUCING AN ANTIOXIDISM, ESPECIALLY FOR USE AS A MEDICINAL PRODUCT | |
| JP3547782B2 (en) | Anti-Helicobacter pylori activator | |
| CN103327993A (en) | Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of gastroesophageal reflux disease | |
| JPH11199497A (en) | Stimulant to organism | |
| CN104825570B (en) | A kind of composition and application thereof inhibiting helicobacter pylori | |
| US11957659B2 (en) | Transmucosal dephosphorylated psychoactive alkaloid composition and preparation thereof | |
| CN106822599A (en) | A kind of dendrobium loddigesii Rolfe extract and its anti-diabetes use | |
| KR20190010578A (en) | New Dapagliflozoline Crystal Forms and Methods of Making and Uses Thereof | |
| JPH0427816B2 (en) | ||
| JP3547783B2 (en) | Prophylactic and therapeutic agent for gastritis and gastric / duodenal ulcer | |
| KR101019733B1 (en) | COMPOSITION COMPRISING EXTRACT OR FRACTION OF Chrysanthemum zawadskii FOR PREVENTING AND TREATING GASTROINTESTINAL DISEASES | |
| KR101055392B1 (en) | Composition comprising the extract of halocynthia roretzi which contains antimicrobial peptide for preventing and treating gastrointestinal diseases | |
| JP3771789B2 (en) | Gastrointestinal hyperkinetic agent | |
| JP3991026B2 (en) | Preventive and therapeutic agent for gastritis and stomach / duodenal ulcer | |
| TWI334783B (en) | Pharmaceutical composition for facilitating the reduction of blood-alcohol concentration after alcohol intake | |
| CA2304493A1 (en) | Flavonolignan preparations, especially silymarin preparations | |
| CN100413500C (en) | Medicine for preventing or treating osteoporosis and its preparing process and application | |
| TWI235663B (en) | Oral liquid preparations | |
| JP4950551B2 (en) | Gastrointestinal mucosa protective agent | |
| JP4786166B2 (en) | Antacid composition | |
| CN115364147B (en) | Fructus Jujubae extract with antioxidant activity and alpha-glucosidase inhibiting activity and its application | |
| JPH10175877A (en) | Urease activity inhibitor of helicobacter pyrroli | |
| KR102545762B1 (en) | Composition for preventing or treating osteoarthritis comprising Gloiopeltis tenax estract | |
| CN108619273B (en) | Preparation method of plant fruit core oral liquid for treating helicobacter pylori | |
| JP2004018437A (en) | Antitumor composition, ingestion composition and method for controlling animal tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20031224 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040316 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040415 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090423 Year of fee payment: 5 |
|
| LAPS | Cancellation because of no payment of annual fees |